Verona Pharma plc - American Depositary Share (VRNA): Price and Financial Metrics

Verona Pharma plc - American Depositary Share (VRNA): $22.04

0.62 (+2.89%)

POWR Rating

Component Grades













Add VRNA to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where VRNA ranks best; there it ranks ahead of 98.03% of US stocks.
  • VRNA's strongest trending metric is Stability; it's been moving down over the last 141 days.
  • VRNA ranks lowest in Stability; there it ranks in the 18th percentile.

VRNA Stock Summary

  • For VRNA, its debt to operating expenses ratio is greater than that reported by just 10.97% of US equities we're observing.
  • VRNA's price/sales ratio is 19.7; that's higher than the P/S ratio of 94.02% of US stocks.
  • The volatility of VERONA PHARMA PLC's share price is greater than that of 91.96% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to VERONA PHARMA PLC, a group of peers worth examining would be CYCN, RARE, MRUS, AFMD, and FDMT.
  • Visit VRNA's SEC page to see the company's official filings. To visit the company's web site, go to

VRNA Valuation Summary

  • In comparison to the median Healthcare stock, VRNA's EV/EBIT ratio is 268.42% lower, now standing at -12.8.
  • VRNA's EV/EBIT ratio has moved up 5.9 over the prior 67 months.

Below are key valuation metrics over time for VRNA.

Stock Date P/S P/B P/E EV/EBIT
VRNA 2022-11-01 20.1 7.3 -14.7 -12.8
VRNA 2022-10-31 19.5 7.0 -14.2 -12.4
VRNA 2022-10-28 19.6 7.1 -14.3 -12.5
VRNA 2022-10-27 17.5 6.3 -12.8 -10.9
VRNA 2022-10-26 17.7 6.4 -12.9 -11.0
VRNA 2022-10-25 17.1 6.2 -12.5 -10.7

VRNA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VRNA has a Quality Grade of C, ranking ahead of 31.46% of graded US stocks.
  • VRNA's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
  • PPBT, TEVA, and PTE are the stocks whose asset turnover ratios are most correlated with VRNA.

The table below shows VRNA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -8.524
2021-03-31 0 NA -14.982
2020-12-31 0 NA -21.674
2020-09-30 0 NA -13.707
2020-06-30 0 NA -6.646
2020-06-30 0 NA -6.646

VRNA Stock Price Chart Interactive Chart >

Price chart for VRNA

VRNA Price/Volume Stats

Current price $22.04 52-week high $26.44
Prev. close $21.42 52-week low $3.41
Day low $20.80 Volume 724,159
Day high $22.15 Avg. volume 689,968
50-day MA $18.67 Dividend yield N/A
200-day MA $10.35 Market Cap 1.67B

Verona Pharma plc - American Depositary Share (VRNA) Company Bio

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual phosphodiesterase 3 and 4 inhibitor, which is in Phase II clinical trial for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.

VRNA Latest News Stream

Event/Time News Detail
Loading, please wait...

VRNA Latest Social Stream

Loading social stream, please wait...

View Full VRNA Social Stream

Latest VRNA News From Around the Web

Below are the latest news stories about VERONA PHARMA PLC that investors may wish to consider to help them evaluate VRNA as an investment opportunity.

Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know

Verona Pharma PLC American Depositary Share (VRNA) closed at $22.53 in the latest trading session, marking a -0.75% move from the prior day.

Yahoo | January 23, 2023

Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know

Verona Pharma PLC American Depositary Share (VRNA) closed at $23.69 in the latest trading session, marking a -0.96% move from the prior day.

Yahoo | January 17, 2023

The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences

AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.

Yahoo | January 3, 2023

Why These 7 Healthcare Stocks Could Soar in 2023

These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023.

Muslim Farooque on InvestorPlace | January 2, 2023

American Equity and Avis Budget Stock See Action From Activist Investors

Brookfield Asset disclosed a large stake in annuity-products issuer American Equity. Hedge fund SRS Investment reached an amended standstill pact with car-rental firm Avis Budget.

Yahoo | December 30, 2022

Read More 'VRNA' Stories Here

VRNA Price Returns

1-mo -15.65%
3-mo 70.00%
6-mo 258.37%
1-year 254.91%
3-year 300.73%
5-year 82.15%
YTD -15.65%
2022 288.84%
2021 -4.00%
2020 21.74%
2019 N/A
2018 0.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.74 seconds.